The United States and United Kingdom Sign No-Tariff Arrangement on Drugs.

The UK and US have signed a landmark trade agreement that will preserve no tariffs on British drug products entering the American market.

The Terms of the Accord

As part of the deal, the UK has pledged to increase spending on drugs through the NHS. This pledge ensures that import taxes on these key products will be held at nothing for a period of the next three years.

This agreement comes after recent threats to hike import taxes on patented pharmaceutical imports, with increases floated up to one hundred percent.

"This deal between the United Kingdom strengthens the international landscape for new treatments and establishes much-needed fairness to American-British pharmaceutical trade," an announcement noted.

Commercial Impact

Drugs are one of the Britain's biggest goods shipped to the US, which is easily the largest destination for leading British pharmaceutical firms.

Trade data indicate that in the year to the end of the third quarter, the UK shipped drugs totaling billions to the US. This figure represented nearly one-fifth of British export trade in that period.

"This guarantee secures employment, increases investment and paves the way for the UK to become a worldwide center for biotech and pharma," the Business and Trade Secretary commented.

Key UK Commitments

The agreement involves several specific pledges from the UK:

• Revised Affordability Limit: The UK will increase the price threshold at which it considers new treatments to be unaffordable by a quarter.
• Increased NHS Spending: There is a target to raise total health service expenditure on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
• Rebate Cap: The amount manufacturers must pay back to the NHS to stay within budget will be limited at fifteen percent. In the past, refunds topped twenty percent.

Industry Background

This agreement follows a ongoing dispute between the sector and the British authorities over drug pricing and approval rates.

These tensions were intensified by assertions that American customers were charged several times more for the same drugs than patients in the UK and Europe.

Over the last 18 months, several significant pharmaceutical investments in the UK have been delayed or scrapped, while multi-billion-dollar expansions have been directed toward American operations.

A senior figure publicly accepted that the NHS needed to spend more on drugs, noting that its spending on drugs had decreased as a share of its resources over the past decade.